OCTOBER 13, 2025
BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong Kong Injection of US$20 million by the consortium of Asian investors Start of clinical operations in early 2026 A landmark Memorandum of Understanding (MoU) has…